Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients

Pediatric Blood and Cancer

Volumn 50, Issue 4, 2008, Pages 769-771

  Renbarger, Jamie L ^a   McCammack, Kevin C ^a   Rouse, Caroline E ^a   Hall, Stephen D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukemia; Neurotoxicity; Pharmacology; Vincristine

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AFRICAN AMERICAN; ARTICLE; CHILD; CHILDHOOD CANCER; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EXPOSURE; DRUG METABOLISM; EUROPEAN AMERICAN; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PHARMACOGENETICS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; RETROSPECTIVE STUDY; RISK FACTOR;

AFRICAN AMERICANS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CHILD, PRESCHOOL; CONTINENTAL POPULATION GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; NEUROTOXICITY SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; VINCRISTINE;

EID: 40449138996     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21435     Document Type: Article

References (19)

1. McCune J, Lindley C. Appropriateness of maximum dose guidelines for vincristine. Am J Health Syst Pharm 1997;54:1755-1758.
2. Gidding C, Kellie S, Kamps W, et al. Vincristine revisited. Crit Rev Oncol Hematol 1999;29:267-287.
3. Van den Berg H, Desai Z, Wilson R, et al. The pharmacokinetics of vincristine in man: Reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 1982;8:215-219.
4. Gidding C, Meeuwsen-de Boer G, Koopmans P, et al. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol 1999;44:203-209.
5. Jehl F, Quoix E, Leveque D, et al. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res 1991;51:2073-2076.
6. Kajita J, Kuwabara T, Kobayashi H, et al. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metabolism and Disposition 2000;28:1121-1127.
7. Leveque D, Jehl F. Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 1996;31:184-197.
8. Leveque D, Jehl F, Quoix E, et al. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin J Clin Pharmacol 1992;32:1096-1098.
9. Marquet P, Lachatre G, Debord J, et al. Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 1992;42:545-547.
10. Rahmani R, Bruno R, Iliadis A, et al. Clinical pharmacokinetics of the antitumor drug Navelbine (5′-noranhydrovinblastine). Cancer Res 1987;47:5796-5799.
11. Ratain M, Vogelzang N, Sinkule J. Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther 1987;41:61-67.
12. Sethi V, Jackson D, White D, et al. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 1981;41:3551-3555.
13. Wargin W, Lucas V. The clinical pharmacokinetics of vinorelbine (navelbine). Semin Oncol 1994;21:21-27.
14. Jemal A, Thomas A, Murray T, et al. Cancer statistics. CA Cancer J Clin 2002;52:23-47.
15. Pollock B, DeBaun M, Camitta B, et al. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 2000;18:813-823.
16. Dennison JB, Kulanthaivel P, Barbuch RJ, et al. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 2006;34:1317-1327.
17. Zhou X, Placidi M, Rahmani R. Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension. Anticancer Res 1994;14:1017-1022.
18. Kim R, Leake B, Choo E, et al. Identification of functionally variant MDR1 alleles among European Americans and African-Americans. Clin Pharmacol Ther 2001;70:189-199.
19. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391.